Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Peng Zhang
Institutions:
Zhejiang Provincial People's Hospital,
Hangzhou Medical College
Observed institutions:
Chinese Academy of Sciences,
Zhejiang Cancer Hospital,
Zhejiang Provincial People's Hospital,
University of Chinese Academy of Sciences,
Hangzhou Medical College,
Hangzhou Institute of Medicine, Chinese Academy of Sciences
show all 6
ORCID:
0000-0001-9637-2842
Observed ORCID:
0000-0001-9637-2842
OpenAlex ID:
A5078810236
Atezolizumab plus Bevacizumab in Patients with Unresectable or Metastatic Mucosal Melanoma: A Multicenter, Open-Label, Single-Arm Phase II Study
2022
·
Lili Mao
, Meiyu Fang
, et al.
·
Clinical Cancer Research
·
40
ICAM1 antibody drug conjugates exert potent antitumor activity in papillary and anaplastic thyroid carcinoma
2023
·
Peng Zhang
, Changjuan Tao
, et al.
·
iScience
·
20
PDF
Epigenetic Reprogramming Potentiates ICAM1 Antibody Drug Conjugates in Preclinical Models of Melanoma
2024
·
Peng Zhang
, Changjuan Tao
, et al.
·
Advanced Science
·
9
PDF
Safety and feasibility of Claudin18.2 (CLDN18.2)-specific CAR-NK cells in advanced gastrointestinal cancers: a phase 1 trial
2026
·
Liu Yang
, Yupeng Hong
, et al.
·
Research Square
PDF
Integrative Omics Analysis Reveals the Potential Value of CEACAM6 in Pan‐Gastrointestinal Cancers
2026
·
Liying Jin
, Changjuan Tao
, et al.
·
Immunity Inflammation and Disease
PDF
Supplementary Table from Atezolizumab plus Bevacizumab in Patients with Unresectable or Metastatic Mucosal Melanoma: A Multicenter, Open-Label, Single-Arm Phase II Study
2023
·
Lili Mao
, Meiyu Fang
, et al.
Supplementary Figure from Atezolizumab plus Bevacizumab in Patients with Unresectable or Metastatic Mucosal Melanoma: A Multicenter, Open-Label, Single-Arm Phase II Study
2023
·
Lili Mao
, Meiyu Fang
, et al.
Supplementary Table from Atezolizumab plus Bevacizumab in Patients with Unresectable or Metastatic Mucosal Melanoma: A Multicenter, Open-Label, Single-Arm Phase II Study
2023
·
Lili Mao
, Meiyu Fang
, et al.
Supplementary Table from Atezolizumab plus Bevacizumab in Patients with Unresectable or Metastatic Mucosal Melanoma: A Multicenter, Open-Label, Single-Arm Phase II Study
2023
·
Lili Mao
, Meiyu Fang
, et al.
Data from Atezolizumab plus Bevacizumab in Patients with Unresectable or Metastatic Mucosal Melanoma: A Multicenter, Open-Label, Single-Arm Phase II Study
2023
·
Lili Mao
, Meiyu Fang
, et al.
Supplementary Table from Atezolizumab plus Bevacizumab in Patients with Unresectable or Metastatic Mucosal Melanoma: A Multicenter, Open-Label, Single-Arm Phase II Study
2023
·
Lili Mao
, Meiyu Fang
, et al.
Supplementary Table from Atezolizumab plus Bevacizumab in Patients with Unresectable or Metastatic Mucosal Melanoma: A Multicenter, Open-Label, Single-Arm Phase II Study
2023
·
Lili Mao
, Meiyu Fang
, et al.
Supplementary Figure from Atezolizumab plus Bevacizumab in Patients with Unresectable or Metastatic Mucosal Melanoma: A Multicenter, Open-Label, Single-Arm Phase II Study
2023
·
Lili Mao
, Meiyu Fang
, et al.
Supplementary Data from Atezolizumab plus Bevacizumab in Patients with Unresectable or Metastatic Mucosal Melanoma: A Multicenter, Open-Label, Single-Arm Phase II Study
2023
·
Lili Mao
, Meiyu Fang
, et al.
Supplementary Table from Atezolizumab plus Bevacizumab in Patients with Unresectable or Metastatic Mucosal Melanoma: A Multicenter, Open-Label, Single-Arm Phase II Study
2023
·
Lili Mao
, Meiyu Fang
, et al.
Supplementary Table from Atezolizumab plus Bevacizumab in Patients with Unresectable or Metastatic Mucosal Melanoma: A Multicenter, Open-Label, Single-Arm Phase II Study
2023
·
Lili Mao
, Meiyu Fang
, et al.
Supplementary Figure from Atezolizumab plus Bevacizumab in Patients with Unresectable or Metastatic Mucosal Melanoma: A Multicenter, Open-Label, Single-Arm Phase II Study
2023
·
Lili Mao
, Meiyu Fang
, et al.
Show more works
View as search
Works count:
17
Citation count:
69
H-index:
3
I10-index:
2
Year
Topic
Type